Synaptogenix Regains Compliance With Nasdaq Minimum Bid Price Requirement for Continued Listing

NEW YORK, April 24, 2024 /PRNewswire/ -- Synaptogenix, Inc. (Nasdaq: SNPX) ("Synaptogenix" or the "Company"), an emerging biopharmaceutical company developing therapeutics for neurodegenerative disor

PR NewswireApr 24 21:15

Synaptogenix Acquires 25% Stake In Cannasoul

According to its most recent 10-K filing as of December 31, 2023, Synaptogenix reported a cash balance of $28.7 million. Additionally, following a recent reverse split, the Company now has approximate

BenzingaApr 9 21:18

Synaptogenix Increases Stake in Innovative Psilocybin Drug Discovery Co Through Its Partnership With Cannasoul Analytics

Synaptogenix Increases Stake in Innovative Psilocybin Drug Discovery Co Through Its Partnership With Cannasoul Analytics

Dow JonesApr 9 21:15

What's Going On With Synaptogenix (SNPX) Stock?

Synaptogenix Inc (NASDAQ:SNPX) shares are trading slightly higher Thursday morning after the company announced a 1-for-25 reverse stock split.This move aims to increase the per-share trading price to

BenzingaApr 4 23:49

Synaptogenix To Carry Out 1-for-25 Reverse Stock Split On April 5th, 2024

April 4th - $Synaptogenix(SNPX.US)$ is about to implement a 1-for-25 reverse stock split of shares. The shares will begin trading on a split-adjusted basis from April 5th, 2024.$Synaptogenix(SNPX.US)$

Futu NewsApr 4 07:40

Synaptogenix Plans 1-for-25 Reverse Stock Split; Shares Fall

Synaptogenix (SNPX) said Wednesday it plans to effect a 1-for-25 reverse split of its common shares to increase the stock's trading price to help the company regain compliance with the Nasdaq Capital

MT NewswiresApr 3 22:43